Adult acute lymphoblastic leukemia.

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Acute lymphoblastic leukemia (ALL) treatment has advanced, leading to recognized subgroups and risk-adapted therapies.
• Understanding ALL biology and cytogenetic-molecular abnormalities drives new therapeutic strategies.
• Successful pediatric ALL treatment adaptations have improved adult complete remission rates.

Purpose of the Study:

• To review the progress in understanding acute lymphoblastic leukemia (ALL) biology and therapy.
• To highlight the impact of pathological classification changes on ALL treatment.
• To discuss the current challenges and future directions in adult ALL therapy.

Main Methods:

• Review of current literature on acute lymphoblastic leukemia (ALL) advancements.
• Analysis of therapeutic outcomes based on ALL subgroups and cytogenetic-molecular profiles.
• Comparison of treatment strategies and survival rates between pediatric and adult ALL patients.

Main Results:

• Risk-adapted therapies and recognition of ALL subgroups have improved outcomes.
• Prognosis has notably improved for mature B-cell ALL and T-cell lineage ALL.
• Adults with ALL achieve similar complete remission rates to children but have inferior long-term survival.

Conclusions:

• Tailored drug development targeting specific cytogenetic-molecular characteristics is crucial for improving adult ALL therapeutic success.
• Further research is needed to bridge the survival gap between pediatric and adult ALL patients.
• Personalized medicine approaches are essential for enhancing long-term outcomes in all acute lymphoblastic leukemia (ALL) patients.